



Универзитет у Београду
Већу групације медицинских наука
н/р секретару: Татјана Субашић Николић
Студентски трг 1
11000 Београд

174113
13.9.2021.

Поштована,

У прилогу овог дописа достављамо Вам материјал за избор проф. др Гуенке Иванове Петрове, редовног професора на Фармацеутском факултету Медицинског Универзитета у Софији, Република Бугарска, у звање гостујућег професора на Универзитету у Београду-Фармацеутском факултету и то:

- Образложење за ангажовање
- Табеларни приказ испуњености услова из члана 3. Правилника о условима и начину ангажовања гостујућих професора на Универзитету у Београду
- Биографија
- Библиографија
- Одлука Наставно-научног већа Факултета број 1714/2 од 10.09.2021. године

С поштовањем,

ЗА ДЕКАН ФАКУЛТЕТА
Проф. др Слађана Шобајић



Слађана Шобајић

1. Образложење

Проф. Гуенка Петрова је редовни професор Фармацеутског факултета, Медицинског Универзитета у Софији. 1984. је магистрирала на Фармацеутском факултету у Софији, а 1991. на Економском Универзитету такође у Софији. Проф. Петрова завршила је специјалистичке студије из области економије фармацеутске праксе и из области економије фармацеутске производње. Докторирала је 1994. године на Фармацеутском факултету Медицинског Универзитета у Софији, а 2003. је добила звање Doctor of Science Degree на Медицинском Универзитету у Софији.

Постигнућа и допринос проф. Петрове у развоју образовања у области фармакоекономије и фармацеутске легислативе су од великог значаја не само у оквиру Медицинског Универзитета у Софији већ и у земљама из окружења. То је верификовано кроз велики број ангажовања на европским Универзитетима. Учествоје у извођењу теоријске и практичне наставе у оквиру интегрисаних академских студија на обавезним предметима социјална фармација и фармацеутска легислатива, фармакоекономија, фармацеутска брига, и на изборним предметима фармацеутски бизнис на Фармацеутском факултету, Медицинског универзитета у Софији. Укључена је и у извођење теоријске наставе за кандидате на специјалистичким академским студијама из економије фармацеутске праксе и економије фармацеутске производње. Проф. Птррова је била гостујући професор на Университету у Нанту, Француска, у Карол Давилла у Румунији и већем броју факултета из окружења.

Руководилац и сарадник је на више пројеката: Хоризон 2020 (Project HTx- Next generation health technology assessment); COST (ENABLE) пројекат; Erasmus+ пројекат „KA2 ReePhepus“; Erasmus+ JoC Joint master degree on HTA; Serbia 2002 - European Agency for Reconstruction Project Short term expert on “Procurement and distribution of drugs”; United Kingdom 2002 – C3O и London School of economics пројекат “TRIPS and access to medicines”; Македонија 2000 – C3O програм “The pharmaceutical sector reform in FYR Macedonia”; Консултант C3O у делу за успостављање националне политике о лековима - NDP Establishment Romania - 1999 – 2000; Harmonisation and application of legislation in the pharmaceutical sector (EU Romania PHARE Project No: RO/97/12/L003); Sweden 1999 – Karolinska Institute, Department of public health science, Division of international health, National drug policy research and development project; Bosnia

Herzegovina- 1998 PHARE BH – Health 03-97 “Pharmaceutical sector development area objective: NDP development and implementation; 1999 - Patient file and patient counselling program – PSF (Pharmaciens sans frontiere); Switzerland 1997-1998 World health organization – Project on National drug policy comparative analysis; Russia 1996 –TACIS project “Индикаторы для национальной лекарственной политики”; и учествовала је на домаћим пројектима из здравствено економске и фармакоекономске анализе, проучавање терапије и употребе лекова за хронична обољења.


Објавила је више од 300 научних радова публикованих у међународним часописима у целини, више од 100 саопштења на међународним конгресима ИСПОР-а и слично.

Члан је Оснивачког одбора ИСПОР Бугарске и председник до 2021. Од 2013. - 2019. године била је председник ИСПОР Централне и Источне Еуропе. Члан је Руководећег одбора научног друштва за Фармацеутске науке Бугарске.

Сходно свему наведеном и приказу испуњених услова из Правилника у табели 1 предлажем ННВ Фармацеутског факултета да се сагласи са предлогом да проф. др Генка Петрова буде изабрана за гостујућег професора Универзитета у Београду .- Фармацеутског факултета.

Руководилац САС Фармакоекономија и фармацеутска легислатива

Проф. др Драгана Лакић



2. Табла 1. Исполненост услова из члана 3. Правилника

ИМЕ И ПРЕЗИМЕ: Проф др. Генка Петрова, Фармацеутски факултет медицинског Универзитета у Софији, Бугарска	
Радови у водећим међународним часописима (наведени су радови из часописа катеорије M21 од 2017. године)	Објавила је више од 300 радова. У периоду од 2017 до 2021. публиковала је 40 радова у врхунским међународним часописима, категорије M21: 1. T Ágh, JFM van Boven, B Wettermark, E Menditto, H Pinnock, I Tsiligianni, G Petrova et al. A cross-sectional survey on medication management practices for noncommunicable diseases in Europe during the second wave of the COVID-19 pandemic. <i>Frontiers in Pharmacology</i> 2021; 12: 1433 2. M Kamusheva, M Dimitrova, K Tachkov, G Petrova, Z Mitkova. Pharmacotherapeutic Patterns and Patients' Access to Pharmacotherapy for Some Rare Diseases in Bulgaria—A Pilot Comparative Study. <i>Frontiers in Pharmacology</i> 2021; 12 3. KP Malinowski, P Kawalec, W Trąbka, M Czech, G Petrova, M Manova, et al. Reimbursement legislations and decision making for orphan drugs in Central and Eastern European countries. <i>Frontiers in pharmacology</i>, 2019; 10, 487 4. Z Mitkova, K Mitov, V Valov, M Manova, A Savova, M Kamusheva, ... <i>Frontiers in pharmacology</i> 2019; 10, 364 5. V Boyadzhieva, N Stoilov, M Ivanova, G Petrova, R Stoilov. Real world experience of disease activity in patients with rheumatoid arthritis and response to treatment with Varios biologic DMARDs. <i>Frontiers in pharmacology</i> 2018; 9, 1303 6. M Manova, A Savova, M Vasileva, S Terezova, M Kamusheva, D Grekova, G Petrova et al. Comparative price analysis of biological products for treatment of rheumatoid arthritis. <i>Frontiers in pharmacology</i> 2018; 9, 1070 7. M Kamusheva, M Manova, AT Savova, GI Petrova, K Mitov, A Harsányi. Comparative analysis of legislative requirements about patients' access to biotechnological drugs for rare diseases in Central and Eastern European Countries. <i>Frontiers in pharmacology</i> 2018; 9, 795 8. VV Boyadzhieva, N Stoilov, RM Stoilov, K Tachkov, M Kamusheva, K Mitov, G Petrova. Quality of life and cost study of rheumatoid arthritis therapy with biological medicines. <i>Frontiers in pharmacology</i> 2018; 9, 794 9. P Kawalec, T Tesar, L Vostalova, P Draganic, M Manova, A Savova, G Petrova et al. Pharmaceutical regulation in Central and Eastern European countries: a current review. <i>Frontiers in pharmacology</i> 2017; 8, 892 10. Vella Bonanno, M Ermisch, B Godman, AP Martin, J Van Den Bergh, ...G. petrova et al. Adaptive pathways: possible next steps for payers in preparation for their potential implementation. <i>Frontiers in pharmacology</i> 2017; 8, 497 36 11. P Kawalec, E Stawowczyk, T Tesar, J Skoupa, A Turcu-Stiolica, ...G Petrova et al. Pricing and reimbursement of biosimilars in Central and Eastern European countries. <i>Frontiers in pharmacology</i> 2017; 8, 288 12. E Diogene, P Vella Bonanno, M Ermisch, B Godman, A Martin, ...G Petrova, et al. Adaptive Pathways: possible Next Steps for Payers in Preparation for Their Potential Implementation, <i>Frontiers in Pharmacology</i>, 2017

13. B Godman, M Haque, T Leong, E Allocati, S Kumar, S Islam, J Charan, G Petrova et al. The Current Situation Regarding Long-Acting Insulin Analogues Including Biosimilars Among African, Asian, European, and South American Countries; Findings and Implications. *Frontiers in public health*, 2021
14. R Daubner-Bendes, S Kovács, M Niewada, M Huic, M Drummond, ...G Petrova et al. Quo Vadis HTA for medical devices in Central and Eastern Europe? Recommendations to address methodological challenges. *Frontiers in public health* 2021; 8, 994
15. Z Mitkova, G Petrova. Analysis of the household and health care system expenditures in Bulgaria. *Frontiers in Public Health* 2021; 9
16. M Kamusheva, S Vandeve, K Mitov, Y Rusenova, A Elenkova, G Petrova et al. New epidemiological, clinical and economic data for patients with acromegaly in Bulgaria. *Frontiers in public health* 2020; 8, 147
17. ZE Mitkova, M Vasileva, AT Savova, M Manova, S Terezova, GI Petrova. Comparison of cardiovascular medicines prices in four European countries. *Frontiers in Public Health* 2020; 8, 433
18. K Tachkov, M Kamusheva, K Mitov, M Doneva, G Petrova. Pilot study on the cost of some oncohematology diseases in Bulgaria. *Frontiers in public health* 2019; 7, 70
19. M Kamusheva, M Vassileva, A Savova, M Manova, G Petrova. An overview of the reimbursement decision-making processes in Bulgaria as a reference country for the middle-income European countries. *Frontiers in public health* 2018; 6, 61
20. Brian Godman, Anna Bucsics, Patricia Vella Bonanno, Wija Oortwijn, Celia C Rothe, Alessandra Ferrario, Simone Bosselli, Andrew Hill, Antony P Martin, Steven Simoens, Amanj Kurdi, Mohamed Gad, Jolanta Gulbinovič, Angela Timoney, Tomasz Bochenek, Ahmed Salem, Iris Hoxha, Robert Sauermann, Amos Massele, Augusto Alfonso Guerra Jr, Guenka Petrova, Zornitsa Mitkova, Gnosia Achniotou, Ott Laius, Catherine Sermet, Gisbert Selke, Vasileios Kourafalos, John Yfantopoulos, Einar Magnusson, Roberta Joppi, Margaret Oluka, Hye-Young Kwon, Arianit Jakupi, Francis Kalemeera, Joseph O Fadare, Oyvind Melien, Maciej Pomorski, Magdalene Wladysiuk, Vanda Marković-Peković, Ileana Mardare, Dmitry Meshkov, Tanja Novakovic, Jurij Fürst, Dominik Tomek, Corrine Zara, Eduardo Diogene, Johanna C Meyer, Rickard Malmström, Björn Wettermark, Zinhle Matsebula, Stephen Campbell, Alan Haycox. Barriers for Access to New Medicines: searching for the Balance Between Rising Costs and Limited Budgets. *Front Public Health*. 2018; 6: 328. doi: 10.3389/fpubh.2018.00328.
21. M Kamusheva, K Tachkov, M Dimitrova, Z Mitkova, G García-Sáez, G petrova et al. A Systematic Review of Collective Evidences Investigating the Effect of Diabetes Monitoring Systems and Their Application in Health Care. *Frontiers in endocrinology* 2021; 12, 178
22. K Tachkov, Z Mitkova, V Boyadzieva, G Petrova. Did the Introduction of Biosimilars Influence Their Prices and Utilization? The Case of Biologic Disease Modifying Antirheumatic Drugs (bDMARD) in Bulgaria. *Pharmaceuticals* 2021; 14 (1), 64
23. KP Malinowski, P Kawalec, W Trąbka, C Sowada, G Petrova, M Manova, et al. Health technology assessment and reimbursement policy for oncology orphan

drugs in Central and Eastern Europe. *Orphanet journal of rare diseases* 2020; 15 (1), 1-13

24. M Szegedi, T Zelei, F Arickx, A Bucsecs, E Cohn-Zanchetta, J Fürst, ...The European challenges of funding orphan medicinal products. *Orphanet journal of rare diseases* 2018; 13 (1), 1-8
25. D Ignatova, M Kamusheva, G Petrova, G Onchev. Costs and outcomes for individuals with psychosis prior to hospital admission and following discharge in Bulgaria. *Social psychiatry and psychiatric epidemiology* 2019; 54 (11), 1353-136
26. VP Rupel, M Divjak, Z Zrubka, F Rencz, L Gulácsi, D Golicki, G Petrova et al. EQ-5D studies in nervous system diseases in eight Central and East European countries: a systematic literature review. *The European Journal of Health Economics*, 2019; 20 (1), 109-117
27. A Ferrario, D Arāja, T Bochenek, T Čatić, D Dankó, M Dimitrova, J Fürst, ..G Petrova et al. The implementation of managed entry agreements in Central and Eastern Europe: findings and implications. *Pharmacoeconomics* 2017; 35 (12), 1271-1285
28. AM Rotar, A Preda, O Löblová, V Benkovic, S Zawodnik, L Gulacsi, G petrova et al. Rationalizing the introduction and use of pharmaceutical products: The role of managed entry agreements in Central and Eastern European countries. *Health Policy* 2018; 122 (3), 230-236
29. M Dimitrova, K Pavlov, K Mitov, J Genov, GI Petrova. Chronic hepatitis c-related cirrhosis hospitalization cost analysis in Bulgaria. *Frontiers in medicine* 2017; 4, 125
30. F Rencz, L Gulácsi, M Drummond, D Golicki, VP Rupel, J Simon, EA Stolk, G petrova et al. EQ-5D in central and Eastern Europe: 2000–2015. *Quality of Life Research* 2016; 25 (11), 2693-2710
31. K Tachkov, Z Mitkova, P Milushewa, G Petrova. Biosimilar Insulins and Their Impact on Prices and Utilization of Insulins in Bulgaria. *Healthcare* 2021; 9 (6), 69
32. E Moorkens, AG Vulto, I Huys, P Dylst, B Godman, S Keuerleber, B Claus, ...G Petrova et al. Policies for biosimilar uptake in Europe: an overview. *PloS One* 2017; 12 (12), e0190147
33. K Tachkov, K Mitov, Y Koleva, Z Mitkova, M Kamusheva, M Dimitrova, G petrova et al. Life expectancy and survival analysis of patients with diabetes compared to the non diabetic population in Bulgaria. *PloS one* 2020; 15 (5), e0232815
34. B Godman, C Grobler, M Van-De-Lisle, J Wale, WB Barbosa, A Massele, ...G petrova et al. Pharmacotherapeutic interventions for bipolar disorder type II: addressing multiple symptoms and approaches with a particular emphasis on strategies in lower and middle-income countries. *Expert opinion on pharmacotherapy* 2019; 20 (18), 2237-2255
35. O Tkachova, L Iakovlieva, Z Mitkova, M Manova, A Savova, G Petrova. An affordability of statins therapy-comparative analysis between Ukraine and Bulgaria. *BMC health services research* 2019; 19 (1), 1-8
36. Inotai, A. , Petrova, G., Vitezic, D, Kaló, Z. Benefits of investment into modern medicines in Central-Eastern European countries (Review). *Expert Review of Pharmacoeconomics and Outcomes Research*. Volume 14, Issue 1, February 2014, Pages 71-79
37. M Dimitrova, K Tachkov, G Petrova. Economic consequences of the

	implementation of national screening program for chronic HCV infection. Expert review of pharmacoeconomics & outcomes research 2020; 20 (4), 397-404 38. K Kolasa, W Goettsch, G Petrova, A Berler. Without data, you're just another person with an opinion. Expert review of pharmacoeconomics & outcomes research 2020; 20 (2), 147-154 39. M Vassileva, M Kamusheva, M Manova, A Savova, K Tachkov, G Petrova. Historical overview of regulatory framework development on pricing and reimbursement of medicines in Bulgaria. Expert review of pharmacoeconomics & outcomes research 2019; 19 (6), 733-742 40. P Vella Bonanno, A Bucsics, S Simoens, AP Martin, W Oortwijn, ...G Petrova, et al. Proposal for a regulation on health technology assessment in Europe—opinions of policy makers, payers and academics from the field of HTA. Expert review of pharmacoeconomics & outcomes research 2019; 19 (3), 251-26
Радови саопштени на међународним скуповима	У периоду од 2015. до 2021. објавила је више од 40 саопштења на међународним скуповима: 1. I Tsekov, B Topova, P Doychev, M Dimitrova, G Petrova. ANALYSIS OF THE TIME TO MARKET ACCESS IN BULGARIA OF NEW DAA MEDICINES FOR CHRONIC HCV INFECTION AUTHORIZED UNDER THE EMA SPECIFIC PROCEDURES FOR EARLY ACCESS. VALUE IN HEALTH 2020; 23, S566-S566 2. Z Mitkova, G Petrova. IMPACT of Generic Competition on Reference Price per DDD and Reimbursed Costs on Antihyperlipidemic Medicines. Value in Health 2020; 23, S500 3. Y Seitaridou, M Kamusheva, P Panayotov, M Dimitrova, G Petrova. Cost and Patients Access Analysis to Reimbursed Medicines for Multiple Sclerosis in Bulgaria. Value in Health 2020; 23, S638 4. I Tsekov, B Topova, P Doychev, M Dimitrova, G Petrova. Analysis of the Time to Market Access in Bulgaria of New Daa Medicines for Chronic HCV Infection Authorized UNDER the EMA Specific Procedures for EARLY Access. Value in Health 2020; 23, S567 5. K Tachkov, D Petrova, M Kamusheva, M Dimitrova, O Georgiev, G Petrova. Three YEARS Follow up of a Representative Cohort of COPD Patients in Bulgaria. Value in Health 2020; 23, S722-S723 6. M Dimitrova, Z Mitkova, G Petrova. Economic IMPACT of Implementation of Next Generation Sequencing (NGS) and Adoption of Molecularly Guided Treatment Options (MGTOs) into Routine Oncology Practice in Bulgaria. Value in Health 2020; 23, S688 7. J Tamer, J Grozev, M Kamusheva, G Petrova. ACCESS OF BULGARIAN PATIENTS TO BIOSIMILAR MEDICINES. Value in Health 2019; 22, S787 8. Z Mitkova, A Savova, M Manova, M Vasileva, S Terezova, G Petrova. ANALYSIS OF ACE-INHIBITORS PRICES IN FOUR EUROPEAN COUNTRIES. Value in Health 2019; 22, S559 9. B Wlodek, M Jakubczyk, M Niewada, L Bojanic, S Zawodnik, S Bojkow, G Petrova et al. EPIDEMIOLOGY, MORTALITY AND STANDARD OF CARE IN ADVANCED BREAST CANCER-A MULTIPLE COUNTRY ANALYSIS. Value in Health 2019; 22, S450

10. K Tachkov, M Kamusheva, D Ignatova, G Petrova. PHARMACOTHERAPY COST AND PRESCRIBING PRACTICE FOR PSYCHOTIC DISORDERS IN BULGARIA. Value in Health 2019; 22, S692
11. Z Mitkova, M Kamusheva, M Doneva, G Petrova. COST ANALYSIS OF REIMBURSED SPENDING ON ACE-INHIBITORS AND SARTANS IN BULGARIA. Value in Health 2019; 22, S547
12. K Tachkov, M Kamusheva, K Mitov, M Doneva, G Petrova. ANALYSIS OF THE COST OF ONCOHEMATOLOGY DISEASES IN BULGARIA. Value in Health 2019; 22, S75-S76
13. K Mitov, V Petkova, K Tachkov, M Kamusheva, M Dimitrova, M Doneva, G Petrova et al. WHAT IS THE LIFE-EXPECTANCY FOR DIABETICS IN BULGARIA? Value in Health 2019; 22, S153
14. M Kamusheva, K Tachkov, M Dimitrova, M Doneva, G Petrova. ASSESSMENT OF SOCIAL AND ECONOMIC BURDEN OF CHRONIC MYELOID LEUKEMIA IN BULGARIA. Value in Health 2018; 21, S456-S456
15. S Georgieva, G Tsvetkova, G Petrova, E Hadjiev, T Haralampieva, et al. HEALTH RELATED QUALITY OF LIFE (HRQOL) IN MULTIPLE MYELOMA (MM) PATIENTS IN BULGARIA. Value in Health 2018; 21, S474
16. Y Rusenova, B Alimanova, D Marinova, M Kamusheva, G Petrova. Pharmacotherapy costs for patients with acromegaly in Bulgaria. Value Health 2018; 21 (3), S451
17. VP Rupel, M Divjak, D Golicki, F Rencz, L Gulácsi, V Brodsky, P Baji, ..G Petrova et al. USE OF EQ-5D IN CENTRAL AND EASTERN EUROPE 2000-2015: NEUROLOGICAL DISORDERS. Value in Health 2018; 21, S323
18. Z Mitkova, V Valov, K Mitov, M Manova, A Savova, M Kamusheva, G Petrova. PDB43-THE COSTS AND RESULTS OF INCRETINS'AND SGLT-2I DIABETES THERAPY IN BULGARIA. Value in Health 2018; 21, S125
19. S Georgieva, G Tsvetkova, G Petrova, E Hadjiev, G Vandova. Analysis Of Health-Related Quality Of Life (HRQOL), And Costs Of Treatment In Chronic Myelogenic Leukemia (CML) In Bulgaria. Value in Health 2017; 20 (9), A554
20. Z Mitkova, M Manova, A Savova, A Stoimenova, G Petrova. Generic competition and its impact on reference pricing system and medicines utilization in the group of sartans. Value in Health 2017; 20 (9), A628
21. M Kamusheva, S Zaharieva, A Elenkova, M Doneva, M Dimitrova, G Petrova. Health-related quality of life and pharmacotherapy costs study for patients with rare endocrine diseases in Bulgaria-A pilot study. Value in Health 2017; 20 (9), A560-A561
22. J Ostrowska, M Jakubczyk, M Niewada, I Lipka, G Petrova, et al. Estimating The Cost of Diabetes-Related Cardiovascular Complications In Selected Central And Eastern European Countries. Value in Health 2017; 20 (9), A476
23. M Kamusheva, M Doneva, M Dimitrova, A Savova, G Petrova. COST ANALYSIS FOR MEDICAL DEVICES FOR RARE DISEASES IN BULGARIA A CASE WITH EPIDERMOLYSIS BULLOSA. VALUE IN HEALTH 2017; 20 (5), A244-A244
24. VP Rupel, E Turk, M Péntek, F Rencz, D Golicki, J Simon, V Brodsky, G Petrova. EQ-5D Studies In Nervous System Diseases In Eight Central And Eastern

- European Countries. Value in Health 2016; 19 (7), A471
25. V Petkova, K Andreevska, D Grekova, G Petrova. Estimation of The Direct Cost of COPD In Bulgaria. Value in Health 2016; 19 (7), A553
 26. G Petrova, Z Mitkova, A Stoimenova, M Manova. Impact of Generic Competition on Changes in Reference Price Per Ddd and Medicines Utilization in the Group of Statins. Value in Health 2016; 19 (7), A660
 27. S Georgieva, G Petrova. Relations between Adherence to Therapy and Quality of Life (Qol) In Cml Patients in Bulgaria. Value in Health 2016; 19 (7), A592
 28. M Dimitrova, G Petrova, M Kamusheva, M Manova, A Savova. Budget and patient access analysis to second line therapy of multiple sclerosis in Bulgaria. Value in Health 2016; 19 (7), A428
 29. M Péntek, F Rencz, D Golicki, VP Rupel, J Simon, V Brodsky, P Baji, ...G petrova, et al. EQ-5D Studies in rheumatology in eight Central and Eastern European Countries. Value in Health 19 (7), A542 1 2016
 30. M Kamusheva, M Doneva, M Dimitrova, A Savova, G Petrova. Annual Cost Analysis for Medicinal Products for Rare Diseases in Bulgaria. Value in Health 2016; 19 (7), A600
 31. G Petrova, S Zaharieva, D Carukciev. Assesment of the Medical and Social Benefits of Incretin-Based Therapy. Value in Health 2016; 19 (3), A71-A7
 32. G Petrova, M Dimitrova, H Voycheva, O Georgiev, D Petrova. COPD Pharmacotherapy In Bulgaria And Its Adherence To Gold Guidelines. Value in Health 2016; 19 (3), A121
 33. T Ágh, A Inotai, L Szilberhorn, J Culig, G Petrova, M Visnansky, Z Kaló. A Novel Method for Calculating Medication Adherence to Poly-Pharmacotherapy by Linking General Practice Prescribing Data and Pharmacy Dispensing Records. Value in Health 2015; 18 (7), A737
 34. L Marinov, M Kamusheva, K Mitov, I Nikolova, G Petrova. A Pilot Study of Direct Costs for Patients With Rheumatoid Arthritis In Bulgaria. Value in Health 2015; 18 (7), A643-A644
 35. M Dimitrova, M Kamusheva, K Mitov, V Petkova, J Dimitrov, G Petrova. New COPD Medicinal Products Entrance Analysis And Their Influence On The Number And Cost Of Hospitalizatos Due To COPD Exacerbations. Value in Health 2015; 18 (7), A499-A500
 36. A Savova, A Stoimenova, M Manova, B Zidarova, G Petrova, N Danchev. Pharmacoeconomic Guideline for Positive Drug List Application Purposes Implemented in Bulgaria. Value in Health 2015; 18 (7), A548
 37. G Petrova, S Georgieva, Y Petrov. Analysis of The Cost of Invasive Fungal Infections In Patients With Hemopoetic Stem Cell Transplantation. Value in Health 2015; 18 (7), A667
 38. M Dimitrova, G Petrova, J Genov, K Pavlov, K Mitov, A Savova. Cost Analysis of The Chronic Hcv-Related Cirrhosis In Bulgaria. Value in Health 2015; 18 (7), A583
 39. M Dimitrova, G Petrova, M Kamusheva, A Savova, M Doneva. Social Burden of Chronic Hcv Infection in Patients with Hepatocellular Carcinoma. Value in Health 2015; 18 (7), A476
 40. F Rencz, L Kemény, JZ Gajdács, W Owczarek, P Arenberger, GS Tiplica, ...G

	Petrova et al. Use of biologics for psoriasis in Central and Eastern European countries. Journal of the European Academy of Dermatology and Venereology 2015; 29 (11), 2222-44 41. M Petrov, M Dimitrova, G Petrova. Cost-Minimization Analysis of Direct Cost of Sevelamer Carbonate and Lanthanum Carbonate in the Treatment of Patients with Chronic Kidney Disease Not on Dialysis in Bulgaria. Value in health regional issues 2015; 7, 94-103
Резултати у оквиру одговарајуће образовне научне области	Од 1986. до 1998. доцент на Катедри за социјалну фармацију и фармакоекономију на Медицинском Универзитету у Софији, Бугарска Од 1998. професор на Катедри за социјалну фармацију и фармакоекономију на Медицинском Универзитету у Софији, Бугарска. Од 2003. гостујући професор на Фармацеутском факултету, Универзитета у Београду, Србија. Од 2006. до 2010. – гостујући професор Универзитета у Нанту (IAE) Од 1998. до 2003. – гостујући професор Медицинског факултета у Букурешту, Сарајеву и Бања Луци. 1993 – 1997 Образовни менаџер СКБ Од 2008-2016 заменик ректора за науку на Медицинском Универзитету у Софији Од 2021 до сада заменик Министра просвете и науке Објавила је 8 књига и 5 уџбеника 1. Петрова Г. и сарадници: „Социјална фармација и фармацевтично законодавство“. Инфофарма, Софија. (Преиздаден 4 пъти) 2. Петрова Г. и сарадници: „Фармакоекономика“, Софија, Инфофарма (Преиздаден 3 пъти) 3. Петкова В. Фармацевтични грижи, Софија, 2015 Учествовала је на већем броју међународних пројеката: Хоризон 2020 (Project HTx- Next generation health technology assessment); COST (ENABLE) пројекат; Erasmus+ пројекат „KA2 ReePhepus“; Erasmus+ JoC Joint master degree on HTA;
Цитираност научних резултата	1018 цитата (620 без аутоцитата), Х индекс 15 према Scopus bazi od 25.8.2021.
Гост уредник међународног часописа	Casopis "Symmetry" – Topic: Application of Symmetry in Biopharmaceuticals: Topics and Advances
Председавао међународним конференцијама	V Конгрес по фармација с међународно учешће, 1-3 април 2011 г., Хисаря VI Конгрес по фармација с међународно учешће, 13 до 16 октомври 2016 г., Сандански
Чланство у уређивачким одборима научних часописа	Pharmacia https://pharmacia.pensoft.net/most_active_editors Biotechnology and Biotechnology equipment (https://www.tandfonline.com/action/journalInformation?show=editorialBoard&journalCode=tbeq20)
Аутор међународне монографије	Regulating pharmaceuticals in Europe: striving for efficiency, equity, and quality, Open University Press, 2004

3. Биографија



Personal information

First name(s) / Surname(s)

Guenka Ivanova Petrova - Tachkova

Address(es)

56 B Rakovski str. 1202, Sofia, Bulgaria

Telephone(s)

+ 3592 9236 545
+ 3592 983 95 75

Mobile:

+ 359 898 55 24 98
+ 359 884 222 964

Fax(es)

+ 359 987 987 4

E-mail

guenka.petrova@gmail.com; gperova@pharmfac.mu-sofia.bg

Nationality

Bulgarian

Date of birth

08.08.1961

Gender

Female

Occupational
field

academic, pharmaceutical, pharmacoconomics

Work experience

Dates

1998 – till now Professor on Social Pharmacy and Pharmacoconomics, Medical University of Sofia (Bulgaria)

Occupation or position held	2003 till now – visiting professor Faculty of Pharmacy, University in Belgrade
	2006 -2010 - visiting professor University of Nantes, IAE
	1998-2003 – visiting professor Medical Universities in Bucharest, Sarajevo, Banja Luka
	1986-1998 Assistant professor on Social Pharmacy, Medical University in Sofia
	Deputy Minister of Education and Science Deputy Rector on Science at the Medical University in Sofia Professor and Assistant Professor, Faculty of Pharmacy at the Medical University Educational manager SKB
Main activities and responsibilities	Lectures with students from IV and V course covering Pharmaceutical legislation; Management Drug supply; NDP; Pharmacoeconomics
	Lecturers in postgraduate courses for professionals on pharmaceutical legislation and pharmacoeconomics
	Researches –more than 400 scientific publications (100 in impact factor journals) and participation in different grant research projects., more than 2000 citations.
	2 Dunav Str., 1000 Sofia, Bulgaria Medical, Pharmaceutical, Pharmacoeconomics
Education and training	
Title of qualification awarded	2004
	Pharmacoeconomics
Principal subjects/occupational skills covered	Distance learning course
	International Society of Pharmacoeconomics and Outcomes research
Name and type of organisation providing education and training	2003
	DSc degree in Pharmacy “Reform in the pharmaceutical sector in transition countries from the Balkan region – analysis of the application of theoretical concepts” .
Title of qualification awarded	Doctor of Science
	Medical University of Sofia
Principal subjects/occupational skills covered	
Name and type of organisation providing education and training	
Dates	1994

Title of qualification awarded	PhD “Drug use and needs-analysis and forecasting”
Principal subjects/occupational skills covered	PhD Degree
Name and type of organisation providing education and training	Medical University of Sofia
Dates	1991-1993
Title of qualification awarded	Specialist
Principal subjects/occupational skills covered	Postgraduate diploma of “Pharmaceutical economy and management”
Name and type of organisation providing education and training	Medical University Sofia, Faculty of Pharmacy
Dates	1997-1999
Title of qualification awarded	Specialist
Principal subjects/occupational skills covered	Postgraduate diploma on “Organization and economy of Pharmaceutical Manufacturing”
Name and type of organisation providing education and training	Medical University Sofia, Faculty of Pharmacy
Dates	1997-1991
Title of qualification awarded	Master of Economics
Principal subjects/occupational skills covered	Economy
Name and type of organisation providing education and training	Higher Economic University in Sofia
Dates	1979-1984
Title of qualification awarded	Master of Pharmacy
Principal subjects/occupational skills covered	Pharmacy

Name and type of organisation providing education and training	Medical University Sofia, Faculty of Pharmacy				
Participation in International Scientific Projects	Horison 2020 – Next generation HTx COST – ENABLE project Serbia 2002 - European Agency for Reconstruction Project Short term expert on “Procurement and distribution of drugs” United Kingdom 2002 – World health organization and London School of economics project “TRIPS and access to medicines” – Macedonia 2000 - Word health organization programme “The pharmaceutical sector reform in FYR Macedonia” – short term consultant of the WHO in the part of the NDP Establishment Romania - 1999 - 2000 Harmonisation and application of legislation in the pharmaceutical sector (EU Romania PHARE Project No: RO/97/12/L003) Sweden 1999 – Karolinska Institute, Department of public health science, Division of international health. National drug policy research and development project. Bosnia Herzegovina - 1998 PHARE BH – Health 03-97 “Pharmaceutical sector development” area objective: NDP development and implementation; 1999 - Patient file and patient counselling program – PSF (Pharmaciens sans frontiere) Switzerland 1997-1998 World health organization – Project on National drug policy comparative analysis Russia 1996 – TACIS project “Индикаторы для национальной лекарственной политики”				
Personal skills and competences	Professor, Manager, Scientists				
Mother tongue(s)	Bulgarian				
Other language(s)	English, Serbo Croation, Russian				
Self-assessment European level (*)					
Language Language	Understanding		Speaking		Writing
	Listening	Reading	Spoken interaction	Spoken production	
	E Excellent	Excellent	Excellent	Excellent	
	S Excellent	Excellent	Excellent	Excellent	
	R Excellent	Excellent	Good	Good	Good

Full name: Guenka Ivanova Petrova-Tachkova
Date: 24/08/2021

4. Библиографија

1. Petrova G., A. Ivanova. Hypertension and common complications – analysis of the ambulatory treatment cost. 2009, Cent Eur J Public Health. 2009 Dec;17(4):223-30
2. Petrova Guenka, Stoimenova Assena, Manova Manoela, Cost-effectiveness of peginterferon (peginterferon alfa-2B) in HCV-infection: a Bulgarian scenario, Archives of the Balkan Medical Union, 2009 (44);3, 2009:215-219
3. Petrova Guenka, Clerfeuille Fabrice, Vakrilova Milena, Mitkov Cvetomir, Poubanne Yannick. The applicability of the tetraclass model to the management of the patient satisfaction in the pharmacies. Pharmacy Practice 2009; (7) 1: 19-28
4. А. Стоименова, Г. Петрова, Добрата Дистрибуторска Практика като част от концепцията за управление на качеството във фармацевтичния сектор, Здравна политика и мениджмънт, 2009 (9);3:75-84
5. G. Petrova, A.Stoimenova, M. Dimitrova, Cost-effectiveness of managing HIV-infection with highly active, combination antiretroviral therapy in Bulgaria, Acta Medica Bulgarica, Vol. XXXVI, 2/2009, pp.,34-42.
6. A. Stoimenova, F. Ribarova, Food supplements for pregnant and lactating women, Acta Medica Bulgarica, Vol. XXXVI, 2/2009, pp.,24-33.
7. Ivanova A. DARVINOVA, Lakic DRAGANA, Andric VESNA, Petrova G. Cost of outpatient hypertension pharmacotherapy - comparative study between Bulgaria and Serbia. Pharmacy Practice 2009 (7); 2
8. Асена Стоименова, Маноела Манова, Георги Драганов, Генка Петрова, Законодателно регламентиране на клиничните изпитвания в България, Международна научна конференция, Стара Загора 4-5.06.2009 г. , Vol. III Medical Biology studies, pp. 29-33.
9. А. Стоименова, М. Манова, Г. Драганов, Г.Петрова, Законодателно регламентиране на клиничните изпитвания в България, International Science conference 4th - 5th June 2009, Stara Zagora, BULGARIA "Economics and Society development on the Base of Knowledge"
10. Petrova G., A. Ivanova. Hypertension and common complications – analysis of the ambulatory treatment cost. 2009, Cent Eur J Public Health. 2009 Dec;17(4):223-30
11. А. Стоименова, М. Мадхи, Г. Петрова, Н. Ламбов, Концепция за добри практики и развитието им в областта на производството на лекарства, Здравна политика и мениджмънт, 2010 (10); 2:68-73.
12. А. Стоименова, М. Мадхи, Г. Петрова, Н. Ламбов, Валидирането като ключов елемент в осигуряването на качеството при производството на лекарства, Здравна политика и мениджмънт, 2010 (10); 2:86-93.
13. Асена Стоименова, Генка Петрова, Фани Рибарова, Съвременни законодателни изисквания за хранителните добавки в България, Здравна политика и мениджмънт, том 10, №4, 2010, 63-70.
14. А. Савова, А. Стоименова, М. Манова, Г. Петрова, Фармакоикономическа оценка на сублингвални таблетки Buprenorfine 2 mg/Naloxone 0,5 mg за лечение на опиоидна наркотична зависимост Медицински преглед, 2010 (XLVI);2:63-70.
15. А. Стоименова, А. Савова, М.Димитрова, М. Манова, Г. Петрова, Анализ на разходите и разход-минимум за фармакотерапия на нелекувани HIV-инфектирани пациенти с Emtricitabine, Scripta periodica, 2010 (XIII); 2:36-44.
16. М. Манова, А. Стоименова, В. Цанкова, А. Савова, Г. Петрова. Фармакоикономическа оценка на Deferiprone, под печат в Scripta periodica, 2010 (XIII);3

17. А. Стоименова, В. Цанкова, А. Савова, М. Манова, Г. Петрова, Фармакотерапия на наркотична и алкохолна оценка на Naltrexone tabl. 50 mg, под печат в Scripta periodica, 2010 (XIII);3, под печат.
18. А. Стоименова, В. Цанкова, А. Савова, М. Манова, Г. Петрова, Фармакоикономическа оценка на приложението на proactant alfa при преждевременно родени деца с респираторен дистрес синдром, Медицински преглед, том XLVII, 2011 г., 1, 70-76.
19. G. Draganov, A. Stoimenova, M. Manova, P. Peikov, G. Petrova, Synephrine and C. Aurantium extract in food supplements: analysis of safety and health claims, Фармация, 2010 (LVII); 1-4: 56-63
20. Petrova Guenka, Stoimenova Assena, Manova Manoela, Cost-effectiveness of celecoxib in patients with familial adenomatous polyposis (FAP): a Bulgarian scenario, Acta Medica Bulgarica, vol. XXXVII, 2010, № 1, 64-70.
21. A. Stoimenova, V. Tzankova, M. Manova, G. Petrova, Cost minimization analysis of inhaled corticosteroids containing beclomethasone dipropionate for asthma therapy, Acta Medica Bulgarica, vol. XXXVII, 2010, № 2, 15-20.
22. Stoimenova, M. Manova, A. Savova, T. Kundurzhiev, M. Stoycheva, S. Georgieva, M. Dimitrova, G. Petrova, Educational project on food supplements for community pharmacists, Acta Medica Bulgarica, vol. XXXVII, 2010, № 2, 51-57.
23. Stoimenova Assena, Dimitrova Maria, Petrova Guenka, Cost-effectiveness of managing chronic HBV infection with adefovir dipivoxil in Bulgaria, Archives of the Balkan Medical Union, vol. 45, no.2, pp.144-148, June 2010.
24. Stoimenova Assena, Manova Manoela, Savova Alexandra, Georgieva Svetla, Dimitrova Maria, Petrova Guenka, Educational project on food supplements for community pharmacists, под печат в Acta Medica Bulgarica, 2010 (XXXVII)
25. Stoimenova Assena, Tzankova Virginia, Manoela Manova, Petrova Guenka, Cost minimization analysis of inhaled corticosteroids containing Beclomethasone dipropionate for asthma therapy, под печат в Acta Medica Bulgarica, 2010 (XXXVII); 2
26. Асена Стоименова, Маноела Манова, Александра Савова, Генка Петрова, Универсални елементи на система за управление на качеството при търговията на едро с лекарства. Отпечатано в пълен текст в сборник с материали от международна научна конференция на СУБ, 2010, Стара Загора.
27. Александра Савова, Асена Стоименова, Маноела Манова, Генка Петрова, Законодателно регламентиране на медицинските изделия в България, Отпечатано в пълен текст в сборник с материали от международна научна конференция на СУБ, 2010, Стара Загора
28. Петрова Г., Асена Стоименова, Александра Савова. Рентабилност на ваксинацията против HPV - световна практика и приложение за България. Мединфо 2010 (X);8: 74-77
29. Manoela Manova, Assena Stoimenova, Fabrice Clerfeuille, Guenka Petrova, Impact of the generic competition on usage and pricess of cardiovascular medicines on the Bulgarian pharmaceutical market, Journal of Public Health Volume 19, Number 1, 91-100, DOI: 10.1007/s10389-010-0352-8
30. Стоименова А., М.Манова, А.Савова, Л.Пейкова, Г.Драганов, Г.Петрова, Суплементация с коензим Q10 на пациенти с хронична сърдечна недостатъчност, Медицински преглед, бр.1, 2011.
31. Боянов М., В. Вълков, О. Хенриксен, Г. Петрова. Моделиране на дългосрочните резултати от подобряването на лечението на захарен диабет тип 2 в България. Ендокринология, 2011, 16 (3), 131-139

32. Stoimenova, G. Petrova, I. Nikolov, M. Manova, G. Draganov, Z. Ivanova, D. Dimitrov, G. Mihova, A. Savova, Continuing professionals' education of Bulgarian pharmacists 2007-2009, *Acta Medica Bulgarica*, 2011, № 1, 90-98.
33. Desancic S., A. Stoimenova, A. Savova, M. Manova, V. Petkova, G. Petrova, Pharmacoeconomics of rare diseases therapy – an example of phenylketonuria, *Acta Medica Bulgarica*, vol. XXXVIII, 2011, № 1, 84-89.
34. Assena Stoimenova, Alexandra Savova, Manoela Manova, Guenka Petrova, The cost of osteoporosis pharmacotherapy and related fractures in Bulgaria, *Acta Medica Bulgarica*, 2012, № 2
35. A. Kostovski, A. Stoimenova, M. Manova, A. Savova, G. Petrova, Therapeutic response prediction in the treatment of chronic leukaemia and possible implications for hospitals, *Compt. rend. Acad. bulg. Sci. Volume 64, Issue No2*, 2011, 277-284
36. G. Petrova, M. Manova, A. Stoimenova, A. Savova, P. Peikov, Cardiovascular medicines prescribing in Bulgaria, *Compt. rend. Acad. bulg. Sci. Volume 64, Issue No2*, 2011, 285-292
37. Ivanova A., G. Petrova, W. Wrona, V. Valov, A. Stoimenova, M. Czech, Modeling long term effects of diabetes therapy: an example of liraglutide, *Compt. rend. Acad. Bulg. Sci. tom 64, №3*, 2011, 449-456.
38. Assena Stoimenova, Manoela Manova, Alexandra Savova, Bistra Angelovska, Guenka Petrova, Reimbursed orphan medicines in Bulgaria and the share of biotechnology-derived products, *Biotechnol. & Biotechnol. Eq.* 2011, 25(2), 2418-2423
39. Guenka Petrova, Manoela Manova, Assena Stoimenova, Alexandra Savova, Plamen Peikov, Utilization and price trends in some reimbursed cardiovascular medicines, *Biotechnol. & Biotechnol. Eq.*, vol.25, 2, 2011, 2424-2431.
40. Assena Stoimenova, Alexandra Savova, Manoela Manova, Bistra Angelovska, Guenka Petrova, Pharmaceutical biotechnology in pharmacy education: USA pharmacy schools, *приета за Biotechnol. & Biotechnol. Eq.*, vol.25, 3, 2011,
41. Maria Dimitrova, Guenka Petrova, Tatiana Cervenjakova, Nina Jancheva, Mona Stefanova, Manoela Manova, Alexandra Savova, Assena Stoimenova. Budget impact model of new antiretroviral biotechnology medicines for treatment of HIV/AIDS patients in Bulgaria. *Biotechnol. & Biotechnol. Eq.*, vol.25, 3, 2011,
42. Manoela Manova, Lily Peikova, Plamen Peikov, Guenka petrova. Patent protection policy in the therapeutic groups of statins. *Biotechnol. & Biotechnol. Eq.*, vol.25, 3, 2011,
43. Petrova Guenka, Anna Ivanova, Marcin Czech, Vasil Valov, Witold Wrona, Maciej Niewada, Alexandra Savova. Liraglutide vs. exenatide in combination with metformin and/or sulfonylurea therapy in type 2 diabetes mellitus therapy in Bulgaria. A modelling study. *Compt. rend. Acad. Bulg. Sci. tom 64, №6*, 2012, 4
44. Lily Peykova, Manoela Manova, Plamen Peikov, Guenka Petrova. Chirality as patent protection policy, *Biotechnol. & Biotechnol. Eq.*, submitted for publication
45. Lakic D., G. Petrova, N. Bogavac, Z. Jelic. *IMPACT OF DISCOUNTING IN PHARMACOECONOMIC MODELING. A CASE STUDY.* *Biotechnol. & Biotechnol. Eq.*, vol.25, 3, 2011
46. Балканска И., А. Стоименова, А. Савова, Г. Петрова. Реимбурсирането на лекарствени продукти в Германия през призмата на стремежа за намаляване на разходите за лекарства *Медицински преглед*, 2012, 48 (4): 66-72
47. Dragana Lakić, Ljiljana Tasić, Mitja Kos, Guenka Petrova, Assena Stoimenova, Dušanka Krajnović. Pharmacy network and access to medicines in selected eastern European countries: comparative analysis. *Croatian Medical Journal*, 2012; 53: 53-9

48. Tycho J. Zuzak,, Johanna Boňková, Domenico Careddu, Miklós Garami, Adamos Hadjipanayis, Janez Jazbec, Joav Merrick, Joyce Miller, Candan Ozturk, Ingrid A.L. Persson, Guenka Petrova, Pablo Saz Peiró, Simon Schraub, A. Paula Simões-Wüst, Aslak Steinsbekk, Karin Stockert, Assena Stoimenova, Jan Styczynski, Alexandra Tzenova-Savova, Søren Ventegodt, Arine M. Vlieger, Alfred Längler. Use of complementary and alternative medicine by children in Europe: Published data and expert perspectives. *Complementary Therapies in Medicine*, doi:10.1016/j.ctim.2012.01.001
49. Alexandra Savova, Guenka Petrova, Aneliya Gotseva, Anna Kurcatova, Mira Koguharova. ECONOMIC ANALYSIS 20 YEARS AFTER THE INTRODUCTION OF UNIVERSAL HBV IMMUNISATION IN BULGARIA. *Biotechnology & Biotechnological Equipment*, Volume 26, Number1, 2012.DOI: 10.5504/bbeq.2011.0141
50. Manoela Manova, Lily Peikova, Plamen Peikov and Guenka Petrova. PATENT PROTECTION POLICY IN THE THERAPEUTIC GROUP OF STATINS. *Biotechnology & Biotechnological Equipment*, Volume 25, Number 4, 20
51. Lakić, Guenka Petrova, Nataša Bogavac-Stanojević, Zorana Jelić-Ivanović. IMPACT OF DISCOUNTING IN PHARMACOECONOMIC MODELING. A CASE STUDY. *Biotechnology & Biotechnological Equipment*, Volume 25, Number 3, 2011, DOI: 10.5504/bbeq.2011.0065
52. Alexandra Savova, Assena Stoimenova, Manoela Manova and Guenka Petrova. Safety aspects of chronic myeloid leukemia pharmacotherapy. *African Journal of Pharmacy and Pharmacology* Vol. 6(8), pp. 525 - 529, 29 February, 2012 DOI: 10.5897/AJPP11.677
53. Svetla Georgieva, Maria Kamusheva, Dragana Lakic, Konstantin Mitov, Alexandra Savova, Guenka Petrova. The health related quality of life for kidney transplant patients in Bulgaria. *Biotechnology & Biotechnological Equipment*, Volume 26, Number 3, 2012
54. Georgieva, S., Savova, A., Paskalev, E., Petrova, G. Literature review on regulatory requirements and medicinal therapy of patients with kidney transplants. *Obshta medicina*. 2012; 14 (3): 3-11
55. М. Димитрова, М. Донева, Г. Петрова. Анализ на бюджетното въздействие в резултат на лечението на есенциална хипертония с нови АТ1-рецепторни антагонисти. *Сърдечно-съдови заболявания* 2013; 44(2):3-8
56. Мария Димитрова, Мария Камушева, Генка Петрова. Литературен обзор на протективната ефикасност, безопасността и фармакоикономическите ползи на ваксинацията против хепатит А. *Наука Фармакология* 2013; 2(7):7-12
57. Бояджиева В.,Р. Стоилов, Г. Петрова. Теоретични основи и значение на фармакоикономическите анализи в ревматологичната практика. *Ревматология* , 2013, 21 (2): 9-17
58. Златарева А., Г. Петрова. Ценообразуване и финансиране на редки заболявания и лекарства сираци (преглед на литературата). *Медицински преглед* , 2013, 49 (4), 31-38
59. М. Манова, Л. Пейкова, М. Димитрова, Г. Петрова. Оценка на бюджетното въздействие при лечение на депресивно разстройство с Escitalopram. *Неврология и психиатрия*, 44, 2013, No 1:36-48
60. Guenka Petrova, Nikolay Mateev, Dimitar Barumov, Lily Peikova, Maria Dimitrova, Manoela Manova. Modeling the customer satisfaction influence on the long term sales: example with leading OTC analgesics INN on national Market. *Modern Economy* 2013; 4:569-575

61. Svetla Georgieva, Guenka Petrova, Maria Dimitrova, Lily Peikova, Emil Paskalev, Jean Filipov, Borelli Zlatkov. Prospective study of the changes in pharmacotherapy cost of adult kidney transplant patients in Bulgaria. *Modern Economy* 2013; 4:827-831
62. Inotai, A. , Petrova, G., Vitezic, D, Kaló, Z. Benefits of investment into modern medicines in Central-Eastern European countries (Review). *Expert Review of Pharmacoeconomics and Outcomes Research*. Volume 14, Issue 1, February 2014, Pages 71-79
63. Boyadzhieva, VI. Stoilov, R., Petrova, G. Theoretical foundations and importance of pharmacoeconomic analyses in rheumatological practice (Review), *Revmatologiya* (Bulgaria), Volume 21, Issue 2, 2013, Pages 9-17
64. Stoimenova, A. , Savova, A., Manova, M., Petrova, G. Quality management in pharmaceutical procurement: Most frequent non-conformities in pharmaceutical wholesalers in Bulgaria, *Biotechnology and Biotechnological Equipment*, Volume 27, Issue 5, 17 October 2013, Pages 4193-4196
65. Kamusheva, M. , Stoimenova, A., Doneva, M., Zlatareva, A., Petrova, G. A cross-country comparison of reimbursed orphan medicines in Bulgaria, Greece and Romania, *Biotechnology and Biotechnological Equipment*, Volume 27, Issue 5, 17 October 2013, Pages 4186-4192
66. Petkova, V., Konstantinova, M. , Petrova, G. Economic evaluation of continuous subcutaneous insulin infusion for children with diabetes - a pilot study: CSII application for children - economic evaluation, *BMC Pediatrics*, Volume 13, Issue 1, 1 October 2013, 155
67. Kamusheva, M.S., Gerasimov, N., Petrova, G.I. Intestinal gel Levodopa + Carbidopa in Parkinson's patients with frequent and prolonged akinesia - an economic evaluation. *International Journal of Pharmaceutical Sciences Review and Research*, Volume 22, Issue 1, October 2013, Article number 44, Pages 244-246
68. Peikova, L., Manova, M., Georgieva, S., Petrova, G. Enantiomers novelty protection and its influence on generic market: An example with escitalopram patent protection. *Biotechnology and Biotechnological Equipment*, Volume 27, Issue 4, 2013, Pages 4044-4047
69. Doneva, M., Valov, V., Borisova, A.-M., Tankova, T., Savova, A., Manova, M., Czech, M., Petrova, G. Comparative analysis of the cost of insulin treated patients in Bulgaria, *Biotechnology and Biotechnological Equipment*, Volume 27, Issue 2, 2013, Pages 3748-3752
70. Peikova, L., Pencheva, I., Petrova, G., Zlatkov, A., Stereo chemical determination of stability of citalopram enantiomers: HPLC chirality test, *International Journal of Pharmaceutical Sciences Review and Research*, Volume 19, Issue 2, March 2013, Pages 7-11
71. Todorova, J., Dantchev, N., Petrova, G. Complex regional pain syndrome acceptance and the alternative denominations in the medical literature, *Medical Principles and Practice*, Volume 22, Issue 3, March 2013, Pages 295-300
72. Bogavac-Stanojević, N., Dopsaj, V., Jelić-Ivanović, Z., Lakić, D., Vasić, D., Petrova, G. Economic evaluation of different screening alternatives for patients with clinically suspected acute deep vein thrombosis. *Biochemia Medica*, Volume 23, Issue 1, 2013, Pages 96-106
73. Savova, A., Kamusheva, M., Georgieva, S., Stoimenova, A., Petrova, G. Budget impact analysis of chronic myeloid leukemia treatment in Bulgaria. *Biotechnology and Biotechnological Equipment*, Volume 27, Issue 1, February 2013, 3595-3598 (Dimitrova, M., Petrova, G. , Manova, M., Savova, A., Yancheva, N., Cervenjakova,

- T., Mitov, K., Stefanova, M. Economic impact of the highly active antiretroviral pharmacotherapy on cost and HIV/AIDS control in Bulgaria. *Biotechnology and Biotechnological Equipment*, (27) 1, 2013, 3599-3604 (Marcheva, M., Tosheva-Konteva, L., Petrova, G. Main legislative changes in healthcare system in Bulgaria during 1997-2012. *Acta Medica Bulgarica*. 2013; 40 (2): 48-59
74. Guenka Petrova et al. PRICING AND REIMBURSEMENT OF MEDICINES IN CENTRAL AND EAST EUROPEAN COUNTRIES. *World Journal of Pharmacy and Pharmaceutical sciences*, 01/2014; 2(6):4311-4328
75. V. Petkova, M. Manova, M. Dimitrov, G. Petrova and N. Lambov, Historical overview of pharmaceutical education in Bulgaria. *African journal of pharmacy and pharmacology* 01/2013; 7 (3): 63-68.
76. Guenka Petrova et al., Mandatory pneumococcal vaccination and its impact on health care budget. *World journal of pharmacy and pharmaceutical sciences*. 01/2013; 2(5):2278-4357.
77. Krklješ Dragana, Nikolay Gerassimov, Guenka Petrova, COMPARATIVE ANALYSIS OF THE REIMBURSED MEDICAL DEVICES IN SERBIA AND BULGARIAp *WORLD JOURNAL OF PHARMACY AND PHARMACEUTICAL SCIENCES*, 2014, Volume 3, Issue 2, 834-843
78. Marina Odalovi, Dragana Lakic, Ivana Tadic, Ljiljana Tasic, Guenka Petrova. How much do we pay for Caesarean section - a pilot study in Serbia, *Acta chirurgica iugoslavica* 2013 Volume 60, Issue 1, Pages: 47-51DOI:10.2298/ACI1301047O
79. Lily Peikova, Ivanka Pencheva, Guenka Petrova, Alexander Zlatkov, Stereo Chemical Determination of Stability of Citalopram Enantiomers: HPLC Chirality Test *Int. J. Pharm. Sci. Rev. Res.*, 19(2), Mar – Apr 2013; n° 02, 7-11
80. Сопотенски Ст., Г. Петрова, А. Червенияков. Ахалазия – хирургични и социални аспекти на диагностиката и лечението. *Медицински преглед*. 2011; (XLVII) 1: 19 – 30
81. Sopotenski St., Al. Cervenyakov. Adapted surgical toracoscopoc Heller's myotomy in the treatment of achalasia. *Acta Medica Bulgarica*, Vol. XXXIX, 2012, № 1:47-55
82. Stoyan Sopotensky, Guenka Petrova, Konstantin Mitov, Alexander Cervenyakov, Danail Petrov. The use of human fibrin sealant – and example for achalasia surgery. *Health Med* 2013; (7) 10: 2806- 2811
83. Албена Златарева, Генка Петрова. Ценообразуване и финансирането на редки заболявания и лекарства сираци (преглед на литературата). *Медицински преглед*, 2013; XLIX (4): 31-39
84. Albena Zlatareva, Dragana Lakic, Maria Kamusheva, Danijela Spaskov, Georgi Momekov, Guenka Petrova. ANALYSIS OF ACCESS TO ORPHAN DRUGS IN FIVE NEIGHBORING EUROPEAN COUNTRIES - BULGARIA, GREECE, MACEDONIA, ROMANIA, AND SERBIA. *World journal of pharmacy and pharmaceutical sciences*, 2013, 2; 6:
85. V. VALOV, M. DONEVA, A.M. BORISOVA, T. TANKOVA, M. CZECH, M. MANOVA, A. SAVOVA, L. PEIKOVA, G. PETROVA. Regional differences in diabetic patients' pharmacotherapy in Bulgaria. *European Review for Medical and Pharmacological Sciences*. 2014; 18: 1499-1506
86. Laszlo Gulacsi, Alexandru M. Rotar, Maciej Niewada, Olga Loblova, Fanni Rencz. Guenka Petrova, Imre Boncz, Niek S. Klazinga. Health technology assessment in Poland, the Czech Republic. Hungary, Romania and Bulgaria. *Eur J Health Econ*: DOI 10.1007/s10198-014-0590-8
87. Petrova Guenka, Konstantin Tachkov, Svetla Georgieva, Maria Dimitrova. Humanistic and economic aspects of hemophilia treatment in Bulgaria: Comparison

- between two therapeutic approaches: prophylactic vs on demand treatment. *Biotechnology and Biotechnology Equipment*, 2014, doi: 10.1080/13102818.2014.926687
88. Dimitrova Maria, Guenka Petrova, K. Tachkov, Maria Bozkova, Maria Kamusheva, Konstantin Mitov. Economic consequences of the vaccination against hepatitis A in the Bulgarian Health care setting. *Biotechnology and Biotechnology Equipment*, 2014, doi: 10.1080/13102818.2014.909654
 89. Albena Zlatareva, Konstantin Tachkov, Milena Stoicheva, Svetla Georgieva, Maria Krasteva Bozhkova, Guenka Petrova. Modelling the Financial Framework of the Pharmacotherapy Cost of Rare Diseases with Orphan Medicines—Part II. *Modern Economy*, 2014, 5, 499-505
 90. Albena Zlatareva, Konstantin Tachkov, Milena Stoicheva, Svetla Georgieva, Georgi Momekov, Guenka Petrova. Financial Analysis of the Access to Pharmacotherapy for Rare Diseases in Bulgaria. *Modern Economy*, 2014, 5, 461-467
 91. Stoimenova A., A. Stoilova, G. Petrova. ISO 9001 certification for hospitals in Bulgaria: does it help service? *Biotechnology and Biotechnology Equipment* 2014, <http://dx.doi.org/10.1080/13102818.2014.915491>
 92. Assena Stoimenova, Alexandra Savova, Svetla Georgieva, Bistra Angelovska, Guenka Petrova. Quality management in hospitals: Analysis of the prescribing practice of cardiovascular medicines. *World Journal of Pharmacy and Pharmaceutical sciences*. 2014; 3 (9):93-102
 93. Lakic Dragana, Branko Petrovic, Guenka Petrova. Cost-effectiveness analysis of different types of labor for singleton pregnancy: real life data. *Spr Arc Cel Lek* 2014; 42 (11-12): 688-694
 94. Borianna Benbassat, Miglena Doneva, Guenka Petrova. Pharmacotherapy Cost of Controlled Ovarian Hyperstimulation of in Vitro Fertilization - A Real Life Study. *Pharmacology & Pharmacy*, 2014, 5, 919-925
 95. Danko David, Guenka Petrova. Health technology assessment in the Balkans: Opportunities for a balanced drug assessment system. *Biotechnology and Biotechnology Eq.* 2014; 28 (6): 1181-1189
 96. Yordanova, S, Petkova, Petrova, G., Dimitrov, M., Naseva, E., Dimitrova, M., Petkova, E. Comparison of health-related quality-of-life measurement instruments in diabetic patients, *Biotechnology and Biotechnology Eq.* 2014; 28 (4): 769-774
 97. B Godman, M Wladysiuk, S McTaggart, A Kurdi, E Allocati, M Jakovljevic, G. Petrova et al. Utilization trend of long-acting insulin analogues including biosimilars across Europe: findings and implications. *BioMed Research International*, 2021
 98. Z Mitkova, M Kamusheva, D Kalpachka, D Ignatova, K Tachkov, G Petrova. Review of medicine utilization for Parkinson's disease management: the Bulgarian perspective. *Journal of Public Health Research*, 2021
 99. B Godman, M Haque, T Leong, E Allocati, S Kumar, S Islam, J Charan, G Petrova et al. The Current Situation Regarding Long-Acting Insulin Analogues Including Biosimilars Among African, Asian, European, and South American Countries; Findings and Implications. *Frontiers in public health*, 2021
 100. B Godman, A Hill, S Simoens, G Selke, I Selke Krulichová, ... G Petrova, et al. Potential approaches for the pricing of cancer medicines across Europe to enhance the sustainability of healthcare systems and the implications. 2021; 4: 1-14
 101. T Ágh, JFM van Boven, B Wettermark, E Menditto, H Pinnock, I Tsiligianni, G Petrova et al. A cross-sectional survey on medication management practices for

- noncommunicable diseases in Europe during the second wave of the COVID-19 pandemic. *Frontiers in Pharmacology* 2021; 12: 1433
102. Z Mitkova, G Petrova. Utilization, Cost, and Affordability of Antihypertensive Therapy in Bulgaria. *Iranian Journal of Pharmaceutical Research* 2021; 20 (2), 403-416
 103. K Tachkov, Z Mitkova, P Milushewa, G Petrova. Biosimilar Insulins and Their Impact on Prices and Utilization of Insulins in Bulgaria. *Healthcare* 2021; 9 (6), 69
 104. K Tachkov, V Boyadzhieva, N Stoilov, K Mitov, G Petrova Is There a Symmetry in Disease Control and Quality of Life of Patients with Rheumatoid Arthritis Treated with Biological Therapy? *Symmetry* 2021; 13 (4), 538
 105. M Kamusheva, K Tachkov, M Dimitrova, Z Mitkova, G García-Sáez, G Petrova et al. A Systematic Review of Collective Evidences Investigating the Effect of Diabetes Monitoring Systems and Their Application in Health Care. *Frontiers in endocrinology* 2021; 12, 178
 106. B Godman, S Simoons, A Kurdi, G Selke, J Yfantopoulos, A Hill, ...G Petrova et al. Variation in the prices of oncology medicines across Europe and the implications for the future. *Generics and Biosimilars Initiative journal* 2021; 10 (2), 72-82
 107. R Daubner-Bendes, S Kovács, M Niewada, M Huic, M Drummond, ...G Petrova et al. Quo Vadis HTA for medical devices in Central and Eastern Europe? Recommendations to address methodological challenges. *Frontiers in public health* 2021; 8, 994
 108. M Kamusheva, M Dimitrova, K Tachkov, G Petrova, Z Mitkova. Pharmacotherapeutic Patterns and Patients' Access to Pharmacotherapy for Some Rare Diseases in Bulgaria—A Pilot Comparative Study. *Frontiers in Pharmacology* 2021; 12
 109. Z Mitkova, G Petrova. Analysis of the household and health care system expenditures in Bulgaria. *Frontiers in Public Health* 2021; 9
 110. M Dimitrova, P Milushewa, E Petrova, D Mihaylova, N Tzvetanova, ...Triple negative breast cancer in Bulgaria: epidemiological data and treatment patterns based on real world evidence and patient registries. *Biotechnology & Biotechnological Equipment* 2021; 35 (1), 551-559
 111. A Turcu-Stiolica, M Bogdan, MS Subtirelu, AD Meca, AE Taerel, I Iaru, G Petrova et al. Influence of COVID-19 on Health-Related Quality of Life and the Perception of Being Vaccinated to Prevent COVID-19: An Approach for Community Pharmacists from Romania and Bulgaria. *Journal of clinical medicine* 2021; 10 (4), 864
 112. K Tachkov, Z Mitkova, V Boyadzhieva, G Petrova. Did the Introduction of Biosimilars Influence Their Prices and Utilization? The Case of Biologic Disease Modifying Antirheumatic Drugs (bDMARD) in Bulgaria. *Pharmaceuticals* 2021; 14 (1), 64
 113. K Tachkov, D Ignatova, K Mitov, M Kamusheva, G Petrova. Trends in the cost and utilization of psychotropic medicines for major psychiatric disorders in Bulgaria from 2013 to 2017. *The European Journal of Psychiatry* 2021; 35 (1), 33-40
 114. I Tsekov, B Topova, P Doychev, M Dimitrova, G Petrova. ANALYSIS OF THE TIME TO MARKET ACCESS IN BULGARIA OF NEW DAA MEDICINES

- FOR CHRONIC HCV INFECTION AUTHORIZED UNDER THE EMA SPECIFIC PROCEDURES FOR EARLY ACCESS. *VALUE IN HEALTH* 2020; 23, S566-S566
115. Z Mitkova, G Petrova. IMPACT of Generic Competition on Reference Price per DDD and Reimbursed Costs on Antihyperlipidemic Medicines. *Value in Health* 2020; 23, S500
 116. Y Seitaridou, M Kamusheva, P Panayotov, M Dimitrova, G Petrova. Cost and Patients Access Analysis to Reimbursed Medicines for Multiple Sclerosis in Bulgaria. *Value in Health* 2020; 23, S638
 117. I Tsekov, B Topova, P Doychev, M Dimitrova, G Petrova. Analysis of the Time to Market Access in Bulgaria of New Daa Medicines for Chronic HCV Infection Authorized UNDER the EMA Specific Procedures for EARLY Access. *Value in Health* 2020; 23, S567
 118. K Tachkov, D Petrova, M Kamusheva, M Dimitrova, O Georgiev, G Petrova. Three YEARS Follow up of a Representative Cohort of COPD Patients in Bulgaria. *Value in Health* 2020; 23, S722-S723
 119. M Dimitrova, Z Mitkova, G Petrova. Economic IMPACT of Implementation of Next Generation Sequencing (NGS) and Adoption of Molecularly Guided Treatment Options (MGTOS) into Routine Oncology Practice in Bulgaria. *Value in Health* 2020; 23, S688
 120. KP Malinowski, P Kawalec, W Trąbka, C Sowada, G Petrova, M Manova, et al. Health technology assessment and reimbursement policy for oncology orphan drugs in Central and Eastern Europe. *Orphanet journal of rare diseases* 2020; 15 (1), 1-13
 121. P Milushewa, M Doneva, G Petrova. Availability and reimbursement of biological products for severe asthma in Bulgaria. *SAGE Open Medicine* 2020; 8, 2050312120951067
 122. M Dimitrova, K Tachkov, G Petrova. Economic consequences of the implementation of national screening program for chronic HCV infection. *Expert review of pharmacoeconomics & outcomes research* 2020; 20 (4), 397-404
 123. K Tachkov, K Mitov, Y Koleva, Z Mitkova, M Kamusheva, M Dimitrova, G petrova et al. Life expectancy and survival analysis of patients with diabetes compared to the non diabetic population in Bulgaria. *PloS one* 2020; 15 (5), e0232815
 124. M Dimitrova, D Lakic, G Petrova, S Bešlija, J Culig. Comparative analysis of the access to health-care services and breast cancer therapy in 10 Eastern European countries. *SAGE open medicine* 2020; 8, 2050312120922029
 125. M Kamusheva, S Vandeva, K Mitov, Y Rusenova, A Elenkova, G Petrova et al. New epidemiological, clinical and economic data for patients with acromegaly in Bulgaria. *Frontiers in public health* 2020; 8, 147
 126. K Kolasa, W Goettsch, G Petrova, A Berler. Without data, you're just another person with an opinion. *Expert review of pharmacoeconomics & outcomes research* 2020; 20 (2), 147-154
 127. M Dimitrova, M Kamusheva, K Tachkov, K Mitov, M Doneva, V Pencheva, G Petrova. Cardiovascular co-morbidity in patients with COPD in Bulgaria. *Biotechnology & Biotechnological Equipment* 2020; 34 (1), 918-924
 128. ZE Mitkova, M Vasileva, AT Savova, M Manova, S Terezova, GI Petrova. Comparison of cardiovascular medicines prices in four European countries. *Frontiers in Public Health* 2020; 8, 433

129. M Kirilova-Doneva, D Pashkouleva, S Sopotensky, G Petrova. Comparison of pre-and post-implantation mechanical behavior of composite hernia meshes. *Journal of Theoretical and Applied Mechanics* 2020; 58
130. B Godman, C Grobler, M Van-De-Lisle, J Wale, WB Barbosa, A Massele, ...G Petrova et al. Pharmacotherapeutic interventions for bipolar disorder type II: addressing multiple symptoms and approaches with a particular emphasis on strategies in lower and middle-income countries. *Expert opinion on pharmacotherapy* 2019; 20 (18), 2237-2255
131. O Tkachova, L Iakovlieva, Z Mitkova, M Manova, A Savova, G Petrova. An affordability of statins therapy-comparative analysis between Ukraine and Bulgaria. *BMC health services research* 2019; 19 (1), 1-8
132. MÅ Jakubczyk, M Niewada, L Bojanic, S Zawodnik, S Bojkow, L Chahoud, .. G Petrova et al. EPIDEMIOLOGY, MORTALITY AND STANDARD OF CARE IN ADVANCED BREAST CANCER-A MULTIPLE COUNTRY ANALYSIS. *ISPOR Europe* 2019
133. M Vassileva, M Kamusheva, M Manova, A Savova, K Tachkov, G Petrova. Historical overview of regulatory framework development on pricing and reimbursement of medicines in Bulgaria. *Expert review of pharmacoeconomics & outcomes research* 2019; 19 (6), 733-742
134. J Tamer, J Grozev, M Kamusheva, G Petrova. ACCESS OF BULGARIAN PATIENTS TO BIOSIMILAR MEDICINES. *Value in Health* 2019; 22, S787
135. Z Mitkova, A Savova, M Manova, M Vasileva, S Terezova, G Petrova. ANALYSIS OF ACE-INHIBITORS PRICES IN FOUR EUROPEAN COUNTRIES. *Value in Health* 2019; 22, S559
136. B Włodek, M Jakubczyk, M Niewada, L Bojanic, S Zawodnik, S Bojkow, G Petrova et al. EPIDEMIOLOGY, MORTALITY AND STANDARD OF CARE IN ADVANCED BREAST CANCER-A MULTIPLE COUNTRY ANALYSIS. *Value in Health* 2019; 22, S450
137. K Tachkov, M Kamusheva, D Ignatova, G Petrova. PHARMACOTHERAPY COST AND PRESCRIBING PRACTICE FOR PSYCHOTIC DISORDERS IN BULGARIA. *Value in Health* 2019; 22, S692
138. Z Mitkova, M Kamusheva, M Doneva, G Petrova. COST ANALYSIS OF REIMBURSED SPENDING ON ACE-INHIBITORS AND SARTANS IN BULGARIA. *Value in Health* 2019; 22, S547
139. D Ignatova, M Kamusheva, G Petrova, G Onchev. Costs and outcomes for individuals with psychosis prior to hospital admission and following discharge in Bulgaria. *Social psychiatry and psychiatric epidemiology* 2019; 54 (11), 1353-136
140. M Doneva, G Petrova, D Petrova, M Kamusheva, V Petkova, K Tachkov, ...Chronic obstructive pulmonary disease exacerbations and progression in relation to ambient air pollutants exposure. *Journal of thoracic disease* 2019; 11 (6), 2490
141. VP Rupel, M Divjak, Z Zrubka, F Rencz, L Gulácsi, D Golicki, G Petrova et al. EQ-5D studies in nervous system diseases in eight Central and East European countries: a systematic literature review. *The European Journal of Health Economics*, 2019; 20 (1), 109-117

142. B Godman, A Hill, S Simoens, A Kurdi, J Gulbinovič, A Martin, A Timoney, ...G Petrova et al. Pricing of oral generic cancer medicines in 25 European countries; findings and implications. *Generics and Biosimilars Initiative Journal* 2019; 8 (2), 49-70
143. KP Malinowski, P Kawalec, W Trąbka, M Czech, G Petrova, M Manova, et al. Reimbursement legislations and decision making for orphan drugs in Central and Eastern European countries. *Frontiers in pharmacology*, 2019; 10, 487
144. P Vella Bonanno, A Bucsis, S Simoens, AP Martin, W Oortwijn, ...G Petrova, et al. Proposal for a regulation on health technology assessment in Europe—opinions of policy makers, payers and academics from the field of HTA. *Expert review of pharmacoeconomics & outcomes research* 2019; 19 (3), 251-261
145. K Tachkov, M Kamusheva, K Mitov, M Doneva, G Petrova. ANALYSIS OF THE COST OF ONCOHEMATOLOGY DISEASES IN BULGARIA. *Value in Health* 2019; 22, S75-S76
146. K Mitov, V Petkova, K Tachkov, M Kamusheva, M Dimitrova, M Doneva, G Petrova et al. WHAT IS THE LIFE-EXPECTANCY FOR DIABETICS IN BULGARIA? *Value in Health* 2019; 22, S153
147. K Tachkov, G Petrova. Budget impact analysis of inhibitor haemophilia a therapy with bypassing agents. *Journal of IMAB—Annual Proceeding Scientific Papers*, 2019; 25 (2), 2511-2515
148. Incretins and SGLT-2i therapy of type 2 diabetes—real life study of their therapeutic and economic effects
149. Z Mitkova, K Mitov, V Valov, M Manova, A Savova, M Kamusheva, ... *Frontiers in pharmacology* 10, 364 1 2019
150. M Kamusheva, V Petkova, G Petrova. A pilot questionnaire-based survey about Bulgarian pharmacists' opinion for implementation of pharmaceutical care for patients with rare diseases. *INTERNATIONAL JOURNAL OF CLINICAL PHARMACY* 2019; 41 (2), 597-597
151. D Ignatova, M Kamusheva, G Petrova, G Onchev. Burden of informal care for individuals with schizophrenia and affective disorders prior to hospital admission. *The European Journal of Psychiatry* 2019; 33 (2), 54-62
152. K Tachkov, M Kamusheva, K Mitov, M Doneva, G Petrova. Pilot study on the cost of some oncohematology diseases in Bulgaria. *Frontiers in public health* 2019; 7, 70
153. M Kamusheva, M Amerikova, G Petrova, I Pencheva. Financial impact of third-generation cephalosporines resistance in hospital settings—an example with ceftriaxone. *European Journal of Hospital Pharmacy* 2019; 26 (Suppl 1), A10-A11
154. G García-Sáez, W Goettsch, JHM Driessen, B Németh, G Petrova, ...Next Generation Health Technology Assessment to support patient-centred, societally oriented, real-time decision-making in Diabetes. 2019
155. M Kamusheva, Y Rusenova, S Vandeva, A Elenkova, S Zaharieva, G Petrova. Economic and pharmaco-economic analysis of acromegaly treatment: a systematic review. *Biotechnology & Biotechnological Equipment* 2019; 33 (1), 1560-1571
156. K Tachkov, K Mitov, Z Mitkova, M Kamusheva, M Dimitrova, V Petkova, G Petrova et al. Improved quality of diabetes control reduces complication costs in Bulgaria. *Biotechnology & Biotechnological Equipment* 2019; 33 (1), 814-820

157. D Ignatova, M Kamusheva, G Petrova, G Onchev. Cost-effectiveness analysis of current treatment of individuals with acute exacerbation of schizophrenia in Bulgaria. *Biotechnology & Biotechnological Equipment* 2019; 33 (1), 204-213
158. M Szegedi, T Zelei, F Arickx, A Bucsics, E Cohn-Zanchetta, J Fürst, ...The European challenges of funding orphan medicinal products. *Orphanet journal of rare diseases* 2018; 13 (1), 1-8
159. V Boyadzhieva, N Stoilov, M Ivanova, G Petrova, R Stoilov. Real world experience of disease activity in patients with rheumatoid arthritis and response to treatment with Varios biologic DMARDs. *Frontiers in pharmacology* 2018; 9, 1303
160. M Kamusheva, K Tachkov, M Dimitrova, M Doneva, G Petrova. ASSESSMENT OF SOCIAL AND ECONOMIC BURDEN OF CHRONIC MYELOID LEUKEMIA IN BULGARIA. *Value in Health* 2018; 21, S456-S456
161. S Georgieva, G Tsvetkova, G Petrova, E Hadjiev, T Haralampieva, et al. HEALTH RELATED QUALITY OF LIFE (HRQOL) IN MULTIPLE MYELOMA (MM) PATIENTS IN BULGARIA. *Value in Health* 2018; 21, S474
162. Y Rusenova, B Alimanova, D Marinova, M Kamusheva, G Petrova. Pharmacotherapy costs for patients with acromegaly in Bulgaria. *Value Health* 2018; 21 (3), S451
163. VP Rupel, M Divjak, D Golicki, F Rencz, L Gulácsi, V Brodsky, P Baji, ..G Petrova et al. USE OF EQ-5D IN CENTRAL AND EASTERN EUROPE 2000-2015: NEUROLOGICAL DISORDERS. *Value in Health* 2018; 21, S323
164. Z Mitkova, V Valov, K Mitov, M Manova, A Savova, M Kamusheva, G Petrova. PDB43-THE COSTS AND RESULTS OF INCRETINS'AND SGLT-2I DIABETES THERAPY IN BULGARIA. *Value in Health* 2018; 21, S125
165. Z Mitkova, K Mitov, V Valov, M Manova, A Savova, M Kamusheva, G Petrova. Medical, social, and economic consequences of type 2 diabetes therapy with medicinal products from the group of DPP-4i, SGLT-2i, and GLP-1 RA. *International Journal of Diabetes in Developing Countries* 2018; 38 (4), 520-521
166. M Manova, A Savova, M Vasileva, S Terezova, M Kamusheva, D Grekova, G Petrova et al. Comparative price analysis of biological products for treatment of rheumatoid arthritis. *Frontiers in pharmacology* 2018; 9, 1070
167. M Kamusheva, M Manova, AT Savova, GI Petrova, K Mitov, A Harsányi. Comparative analysis of legislative requirements about patients' access to biotechnological drugs for rare diseases in Central and Eastern European Countries. *Frontiers in pharmacology* 2018; 9, 795
168. VV Boyadzhieva, N Stoilov, RM Stoilov, K Tachkov, M Kamusheva, K Mitov, G Petrova. Quality of life and cost study of rheumatoid arthritis therapy with biological medicines. *Frontiers in pharmacology* 2018; 9, 794
169. VV Boyadzhieva, N Stoilov, G Petrova, R Stoilov Measuring health related quality of life (EQ-5D) in patients with rheumatoid arthritis after one year treatment with CSDMARDs and biologic DMARDs. *Annals of the Rheumatic Diseases* 2018; 77 (Suppl 2), 566-566
170. M Kamusheva, M Vassileva, A Savova, M Manova, G Petrova. An overview of the reimbursement decision-making processes in Bulgaria as a reference country for the middle-income European countries. *Frontiers in public health* 2018; 6, 61

171. AM Rotar, A Preda, O Löblová, V Benkovic, S Zawodnik, L Gulacsi, G petrova et al. Rationalizing the introduction and use of pharmaceutical products: The role of managed entry agreements in Central and Eastern European countries. *Health Policy* 2018; 122 (3), 230-236
172. M Kamusheva, K Tachkov, G Petrova, A Savova, M Manova. Orphan medicinal products' access to the Bulgarian pharmaceutical market—challenges and obstacles. *Expert Opinion on Orphan Drugs* 2018; 6 (2), 95-104
173. A Inotai, M Csanadi, G Petrova, M Dimitrova, T Bochenek, T Tesar, K York, Patient access, unmet medical need, expected benefits, and concerns related to the utilisation of biosimilars in Eastern European countries: a survey of experts. *BioMed research international*, 2018
174. Brian Godman, Anna Bucsics, Patricia Vella Bonanno, Wija Oortwijn, Celia C Rothe, Alessandra Ferrario, Simone Bosselli, Andrew Hill, Antony P Martin, Steven Simoens, Amanj Kurdi, Mohamed Gad, Jolanta Gulbinovič, Angela Timoney, Tomasz Bochenek, Ahmed Salem, Iris Hoxha, Robert Sauermann, Amos Massele, Augusto Alfonso Guerra Jr, Guenka Petrova, Zornitsa Mitkova, Gnosia Achniotou, Ott Laius, Catherine Sermet, Gisbert Selke, Vasileios Kourafalos, John Yfantopoulos, Einar Magnusson, Roberta Joppi, Margaret Oluka, Hye-Young Kwon, Arianit Jakupi, Francis Kalemeera, Joseph O Fadare, Oyvind Melien, Maciej Pomorski, Magdalene Wladysiuk, Vanda Marković-Peković, Ileana Mardare, Dmitry Meshkov, Tanja Novakovic, Jurij Fürst, Dominik Tomek, Corrine Zara, Eduardo Diogene, Johanna C Meyer, Rickard Malmström, Björn Wettermark, Zinhle Matsebula, Stephen Campbell, Alan Haycox. Barriers for Access to New Medicines: searching for the Balance Between Rising Costs and Limited Budgets. *Front Public Health*. 2018; 6: 328. doi: 10.3389/fpubh.2018.00328.
175. Márta Szegedi, Tamás Zelei, Francis Arickx, Anna Bucsics, Emanuelle Cohn-Zanchetta, Jurij Fürst, Maria Kamusheva, Pawel Kawalec, Guenka Petrova, Juraj Slaby, Ewa Stawowczyk, Milan Vocelka 10, Ingrid Zechmeister-Koss, Zoltán Kaló, Mária Judit Molnár. The European challenges of funding orphan medicinal products *Orphanet J Rare Dis*. 2018 Nov 6;13(1):184. doi: 10.1186/s13023-018-0927-y
176. Z Mitkova, M Manova, A Savova, A Peneva, J Mitkov, OV Tkachova, G petrova. Statins utilization and price variations-comparison between Ukraine and Bulgaria. 2018
177. D Krajnović, J Arsić, L Tasić, G Petrova, S Milijić. Access to orphan drugs: A cross country comparison of legislative approach among Serbia, Croatia and Macedonia. *Acta Medica Medianae* 2018; 57 (4), 43-51
178. M Dimitrova, M Kamusheva, K Mitov, D Grekova, G Petrova. Screening and diagnosis of chronic HCV infection in Bulgaria: a review of the current practice. *BioMedical Res* 2018; 29, 2846-2853
179. DD Grekova, KG Andreevska, G Petrova, V Petkova. Assessment of the social and economic burden of glaucoma in Bulgaria. *Biomedical Research* 2018; 29 (12), 2578-2581
180. P Batóg, F Rencz, M Péntek, L Gulácsi, KJ Filipiak, VP Rupel, J Simon, G Petrova et al. EQ-5D studies in cardiovascular diseases in eight Central and Eastern European countries: a systematic review of the literature. *Kardiologia Polska (Polish Heart Journal)* 2018; 76 (5), 860-870

181. E Moorkens, AG Vulto, I Huys, P Dylst, B Godman, S Keuerleber, B Claus, ...G Petrova et al. Policies for biosimilar uptake in Europe: an overview. *PloS One* 2017; 12 (12), e0190147
182. P Kawalec, T Tesar, L Vostalova, P Draganic, M Manova, A Savova, G Petrova et al. Pharmaceutical regulation in Central and Eastern European countries: a current review. *Frontiers in pharmacology* 2017; 8, 892
183. Z Zrubka, F Rencz, J Zavada, D Golicki, VP Rupel, J Simon, V Brodsky, G Petrova et al. EQ-5D studies in musculoskeletal and connective tissue diseases in eight Central and Eastern European countries: a systematic literature review and meta-analysis. *Rheumatology international* 2017; 37 (12), 1957-1977
184. A Ferrario, D Arāja, T Bochenek, T Čatić, D Dankó, M Dimitrova, J Fürst, ..G Petrova et al. The implementation of managed entry agreements in Central and Eastern Europe: findings and implications. *Pharmacoeconomics* 2017; 35 (12), 1271-1285
185. S Georgieva, G Tsvetkova, G Petrova, E Hadjiev, G Vandova. Analysis Of Health-Related Quality Of Life (HRQOL); And Costs Of Treatment In Chronic Myelogenous Leukemia (CML) In Bulgaria. *Value in Health* 2017; 20 (9), A554
186. Z Mitkova, M Manova, A Savova, A Stoimenova, G Petrova. Generic competition and its impact on reference pricing system and medicines utilization in the group of sartans. *Value in Health* 2017; 20 (9), A628
187. M Kamusheva, S Zaharieva, A Elenkova, M Doneva, M Dimitrova, G Petrova. Health-related quality of life and pharmacotherapy costs study for patients with rare endocrine diseases in Bulgaria—A pilot study. *Value in Health* 2017; 20 (9), A560-A561
188. J Ostrowska, M Jakubczyk, M Niewada, I Lipka, G Petrova, et al. Estimating The Cost of Diabetes-Related Cardiovascular Complications In Selected Central And Eastern European Countries. *Value in Health* 2017; 20 (9), A476
189. B Stancheva, V Pencheva, D Petrova, O Georgiev, M Kamusheva, G. Petrova. Inhaled corticosteroids in stable COPD—international recommendations and reality in Bulgaria. *European Respiratory Journal* 2017; 50 (suppl 61)
190. Vella Bonanno, M Ermisch, B Godman, AP Martin, J Van Den Bergh, ...G. petrova et al. Adaptive pathways: possible next steps for payers in preparation for their potential implementation. *Frontiers in pharmacology* 2017; 8, 49736
191. M Dimitrova, K Pavlov, K Mitov, J Genov, GI Petrova. Chronic hepatitis c-related cirrhosis hospitalization cost analysis in Bulgaria. *Frontiers in medicine* 2017; 4, 125
192. M Kamusheva, K Mitov, M Doneva, A Stoimenova, M Dimitrova, G Petrova. Efficacy and Safety of Reimbursed Orphan Medicines in Bulgaria—Systematic Review and Meta-analysis (Part I). *Journal of Pharmaceutical Research International*, 2017; 1-14
193. P Kawalec, E Stawowczyk, T Tesar, J Skoupa, A Turcu-Stiolica, ...G Petrova et al. Pricing and reimbursement of biosimilars in Central and Eastern European countries. *Frontiers in pharmacology* 2017; 8, 288
194. M Kamusheva, M Dimitrova, JFM van Boven, MJ Postma, T van der Molen, G Petrova et al. Clinical characteristics, treatment patterns, and socio-economic burden of COPD in Bulgaria. *Journal of medical economics* 2017; 20 (5), 503-509

195. M Kamusheva, M Doneva, M Dimitrova, A Savova, G Petrova. COST ANALYSIS FOR MEDICAL DEVICES FOR RARE DISEASES IN BULGARIA A CASE WITH EPIDERMOLYSIS BULLOSA. VALUE IN HEALTH 2017; 20 (5), A244-A244
196. G Petrova, A Stoimenova, M Dimitrova, M Kamusheva, D Petrova, ...Assessment of the expectancy, seriousness and severity of adverse drug reactions reported for chronic obstructive pulmonary disease therapy. SAGE open medicine 2017; 5, 2050312117690404
197. B Benbassat, K Mitov, A Savova, K Tachkov, G Petrova. Cost-effectiveness of different types of COH protocols for in vitro fertilization at national level. Biotechnology & Biotechnological Equipment 2017; 31 (1), 206-214
198. I Popova, L Miteva, M Kamusheva, M Bodenska, G Petrova. Socio-economic burden of psoriasis and its concomitant diseases. General Medicine 2017; 19 (1), 56-68
199. E Diogene, P Vella Bonanno, M Ermisch, B Godman, A Martin, ...G Petrova, et al. Adaptive Pathways: possible Next Steps for Payers in Preparation for Their Potential Implementation, Frontiers in Pharmacology, 2017
200. D Pashkouleva, M Kirilova-Doneva, I Borovanska, AA Apostolov, G Petrova. Identification of explanted hernia meshes of unknown composition. Series on Biomechanics, 2016
201. VP Rupel, E Turk, M Péntek, F Rencz, D Golicki, J Simon, V Brodszky, G Petrova. EQ-5D Studies In Nervous System Diseases In Eight Central And Eastern European Countries. Value in Health 2016; 19 (7), A471
202. V Petkova, K Andreevska, D Grekova, G Petrova. Estimation of The Direct Cost of COPD In Bulgaria. Value in Health 2016; 19 (7), A553
203. G Petrova, Z Mitkova, A Stoimenova, M Manova. Impact of Generic Competition on Changes in Reference Price Per Ddd and Medicines Utilization in the Group of Statins. Value in Health 2016; 19 (7), A660
204. S Georgieva, G Petrova. Relations between Adherence to Therapy and Quality of Life (Qol) In Cml Patients in Bulgaria. Value in Health 2016; 19 (7), A592
205. M Dimitrova, G Petrova, M Kamusheva, M Manova, A Savova. Budget and patient access analysis to second line therapy of multiple sclerosis in Bulgaria. Value in Health 2016; 19 (7), A428
206. M Péntek, F Rencz, D Golicki, VP Rupel, J Simon, V Brodszky, P Baji, ...G petrova, et al. EQ-5D Studies in rheumatology in eight Central and Eastern European Countries. Value in Health 19 (7), A542 1 2016
207. M Kamusheva, M Doneva, M Dimitrova, A Savova, G Petrova. Annual Cost Analysis for Medicinal Products for Rare Diseases in Bulgaria. Value in Health 2016; 19 (7), A600
208. F Rencz, L Gulácsi, M Drummond, D Golicki, VP Rupel, J Simon, EA Stolk, G petrova et al. EQ-5D in central and Eastern Europe: 2000–2015. Quality of Life Research 2016; 25 (11), 2693-2710
209. Z Mitkova, M Manova, S Georgieva, G Petrova. Fixed Doses Combinations Acting on Cardiovascular System-Utilization and Generic Competition. Advances in Research, 2016; 1-14

210. M Jakubczyk, I Lipka, J Pawęska, M Niewada, E Rdzanek, J Zaletel, G petrova et al. Cost of severe hypoglycaemia in nine European countries. *Journal of medical economics* 2016; 19 (10), 973-982
211. A Stoimenova, S Penkov, A Savova, M Manova, G Petrova. Generic policy in Bulgaria: a policy of failure or success? *Biotechnology & Biotechnological Equipment* 2016; 30 (5), 1031-1037
212. Z Mitkova, M Vasileva, A Savova, M Manova, G Petrova. Analysis of cardiovascular medicines prices and reimbursement in Bulgaria and Romania. *Rev. Farm* 2016; 64 (3): 633-642
213. G Petrova, B Benbassat, D Lakic, M Dimitrova, K Mitov, J Dimitrov. Cost-effectiveness of short COH protocols with GnRH antagonists using different types of gonadotropins for in vitro fertilization. *Biotechnology & Biotechnological Equipment* 2016; 30 (3), 614-6212
214. G Petrova, S Zaharieva, D Carukciev. Assesment of the Medical and Social Benefits of Incretin-Based Therapy. *Value in Health* 2016; 19 (3), A71-A72
215. G Petrova, M Dimitrova, H Voycheva, O Georgiev, D Petrova. COPD Pharmacotherapy In Bulgaria And Its Adherence To Gold Guidelines. *Value in Health* 2016; 19 (3), A121
216. G Petrova, M Doneva, Z Mitkova, K Tachkov, M Manova. Generics and fixed-dose combinations in cardiology: satisfaction analysis of pharmacists and cardiologists. *Biotechnology & Biotechnological Equipment* 2016; 30 (1), 204-211
217. Z Mitkova, M Manova, G Petrova. Relationship between generic competition and generic utilization of cardiovascular medicines monoproducts in Bulgaria. *Farmacia* 2016; 63 (4), 3-14 4
218. B Benbassat, Y Dimitrov, G Petrova. Review of the historical development and religious discussions for the assisted reproductive technologies. *Meditinski Pregled Sestrinsko delo/Medical Review-Information for Nursing*, 2016
219. VL Boyadzhieva, N Stoilov, R Stoilov, G Petrova, S Stefanov, ...COST OF TREATMENT OF RHEUMATOID ARTHRITIS, ANKYLOSING SPONDYLITIS AND PSORIATIC ARTHRITIS WITH BIOLOGICAL DISEASE-MODIFYING ANTIRHEUMATIC DRUGS IN THE PERIOD 2013-2014 IN BULGARIA. *JOURNAL OF THE BALKAN TRIBOLOGICAL ASSOCIATION* 2016; 22 (1), 401-409
220. M Kirilova-Doneva, D Pashkouleva, S Sopotensky, G Petrova. Application of light and partially resorbable meshes in Bulgaria. *Series on Biomechanics*, 2015;1
221. ZE Mitkova, KT Tachkov, GI Petrova, MM Manova. Factors influencing generics and fixed dose combinations recommendation by pharmacists for cardiology patients. *African Journal of Pharmacy and Pharmacology* 2015; 9 (43), 1020-1025
222. T Ágh, A Inotai, L Szilberhorn, J Culig, G Petrova, M Visnansky, Z Kaló. A Novel Method for Calculating Medication Adherence to Poly-Pharmacotherapy by Linking General Practice Prescribing Data and Pharmacy Dispensing Records. *Value in Health* 2015; 18 (7), A737
223. L Marinov, M Kamusheva, K Mitov, I Nikolova, G Petrova. A Pilot Study of Direct Costs for Patients With Rheumatoid Arthritis In Bulgaria. *Value in Health* 2015;18 (7), A643-A644

224. M Dimitrova, M Kamusheva, K Mitov, V Petkova, J Dimitrov, G Petrova. New COPD Medicinal Products Entrance Analysis And Their Influence On The Number And Cost Of Hospitalizations Due To COPD Exacerbations. Value in Health 2015; 18 (7), A499-A500
225. A Savova, A Stoimenova, M Manova, B Zidarova, G Petrova, N Danchev. Pharmacoeconomic Guideline for Positive Drug List Application Purposes Implemented in Bulgaria. Value in Health 2015; 18 (7), A548
226. G Petrova, S Georgieva, Y Petrov. Analysis of The Cost of Invasive Fungal Infections In Patients With Hemopoetic Stem Cell Transplantation. Value in Health 2015; 18 (7), A667
227. M Dimitrova, G Petrova, J Genov, K Pavlov, K Mitov, A Savova. Cost Analysis of The Chronic Hcv-Related Cirrhosis In Bulgaria. Value in Health 2015; 18 (7), A583
228. M Dimitrova, G Petrova, M Kamusheva, A Savova, M Doneva. Social Burden of Chronic Hcv Infection in Patients with Hepatocellular Carcinoma. Value in Health 2015; 18 (7), A476
229. F Rencz, L Kemény, JZ Gajdáci, W Owczarek, P Arenberger, GS Tiplica, ...G Petrova et al. Use of biologics for psoriasis in Central and Eastern European countries. Journal of the European Academy of Dermatology and Venereology 2015; 29 (11), 2222-44
230. M Petrov, M Dimitrova, G Petrova. Cost-Minimization Analysis of Direct Cost of Sevelamer Carbonate and Lanthanum Carbonate in the Treatment of Patients with Chronic Kidney Disease Not on Dialysis in Bulgaria. Value in health regional issues 2015; 7, 94-103
231. M Dimitrova, M Doneva, V Valov, S Yordanova, M Manova, A Savova, G Petrova. Cost of hospitalizations due to microvascular and macrovascular complications in type 1 and type 2 diabetic patients in Bulgaria. Biotechnology & Biotechnological Equipment 2015; 29 (4), 805-813
232. M Kirilova-Doneva, D Pashkouleva, V Kavardzhikov, S Sopotensky, G Petrova. Evaluation of mechanical alterations of explanted hernia meshes. Series on Biomechanics 2015; 1
233. D Tcharaktchiev, S Zacharieva, G Angelova, S Boytcheva, Z Angelov, G Petrova et al. Building a bulgarian national registry of patients with diabetes mellitus. Bulgarian Journal of Social Medicine 2015; 2, 19-21
234. Z Mitkova, P Milushewa, A Zlatareva, M Manova, K Tachkov, G Petrova. STUDY THE CARDIOLOGISTS' KNOWLEDGE AND PERCEPTION ABOUT GENERIC AND FIXED DOSE COMBINATION MEDICINES IN CARDIOLOGY. PHARMACIA 2015; 62 (4), 22-29

УНИВЕРЗИТЕТ У БЕОГРАДУ
ФАРМАЦЕУТСКИ ФАКУЛТЕТ
11000 Београд
01 бр. 1741/2
10.09.2021.

На основу члана 28. став 1. тачка 21. Статута Универзитета у Београду-
Фармацеутског факултета, Наставно-научно веће Фармацеутског факултета на седници
одржаној 09.09.2021. године, донело је

ОДЛУКУ

Утврђује се предлог за избор проф. др Гуенке Иванове Петрове, редовног
професора на Фармацеутском факултету Медицинског Универзитета у Софији,
Република Бугарска, у звање гостујућег професора на Универзитету у Београду-
Фармацеутском факултету.

Одлуку доставити: Већу групације медицинских наука Универзитета у Београду,
декану, секретару, Одсеку за наставу и студентска питања, Одсеку за правне и опште
послове, пословном секретару и архиви

39 ПРЕДСЕДНИК
НАСТАВНО-НАУЧНОГ ВЕЋА
Проф. др Слађана Шобајић

Слађана Шобајић

